Shorter steroid treatment for large artery inflammation
Treatments studied
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests if a shorter course of the steroid prednisone, combined with tocilizumab, works as well as a longer course for giant cell arteritis. You must already be starting tocilizumab and taking at least 20 mg of prednisone daily.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have giant cell arteritis, a condition causing inflammation in large arteries.
- You are starting treatment with tocilizumab as part of your usual care.
- You take at least 20 mg of prednisone (or another steroid) each day at the start of the study.
- You provide written consent to participate.
- You have not taken any experimental drug in the last 30 days or 5 half-lives (whichever is longer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug tocilizumab (Actemra) to see if it helps reduce swelling in the aorta in people with giant cell arteritis (GCA) who are newly diagnosed or have had a flare. It may offer a targeted treatment for aortitis without using high-dose steroids.
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
This study tracks patients with giant cell arteritis (GCA, a blood vessel inflammation affecting older adults) who are in remission and tapering their steroid medications. Researchers will monitor disease activity through blood tests and patient questionnaires to understand if their condition stays stable as they reduce treatment.
This trial tests whether the drug upadacitinib can help people with giant cell arteritis (GCA) that affects the large blood vessels, such as the aorta. It is for those who have not responded to, cannot tolerate, or cannot use another treatment called tocilizumab.
This study is for people with giant cell arteritis (GCA), a condition where blood vessels become inflamed. It tests a drug called rituximab to see if it can help by targeting special immune cells (B cells). The study uses scans to look at inflammation in the large blood vessels. You must have active GCA in the large vessels (shown by a scan in the last 4 weeks), be over 50, and start treatment with steroids alone (no other immune-suppressing drugs yet). You cannot have been on steroids for more than 4 weeks before joining.
This study measures how C-reactive protein (CRP), a marker of inflammation, changes in people with giant cell arteritis after they start taking steroids. It aims to understand the body's response to treatment and help guide future care.
Hear when a new Giant Cell Arteritis (GCA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.